Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0392680 (
shortness of breath
)
5,217
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This study tested the hypothesis that patients with
PAD
have impaired health-related quality of life (HRQoL) to a degree similar to that of patients with other types of cardiovascular disease (other-CVD), and also evaluated the clinical features of
PAD
associated with impaired HRQoL. This was a cross-sectional study in 350 primary care practice sites nationwide with 6,499 participants. The reference group had no clinical or hemodynamic evidence of
PAD
or other-CVD; the
PAD
group had an ankle-brachial index < 0.90 or a prior history of
PAD
; the other-CVD group had a clinical history of cardiac or cerebral vascular disease (but no
PAD
), and the combined
PAD
-other-CVD group included both diagnoses. Individuals were assessed using four HRQoL questionnaires including the Walking Impairment Questionnaire (WIQ), Medical Outcomes Study SF-36 (SF-36), Cantril Ladder of Life and the
PAD
Quality of Life questionnaire.
PAD
patients had lower WIQ distance scores than the other-CVD group. Both the
PAD
and other-CVD groups had significantly lower SF-36 Physical Function scores compared with the reference group. The WIQ revealed that
PAD
patients were more limited by calf pain, whereas other-CVD patients were more limited by chest pain,
shortness of breath
and palpitations. In conclusion, in this nationwide study, one of the first to directly compare the HRQoL burden of CVD with that of
PAD
, the evaluation of
PAD
in office practice revealed a HRQoL burden as great in magnitude as in patients with other forms of CVD.
...
PMID:The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. 1837 34